SCYNEXIS INC (SCYX)
US8112922005 - Common Stock
We assign a fundamental rating of 2 out of 10 to SCYX. SCYX was compared to 193 industry peers in the Pharmaceuticals industry. SCYX may be in some trouble as it scores bad on both profitability and health. SCYX does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
In the past year SCYX has reported negative net income.
SCYX had a negative operating cash flow in the past year.
SCYX had negative earnings in 4 of the past 5 years.
SCYX had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
SCYX has a Return On Assets (-36.79%) which is in line with its industry peers.
SCYX's Return On Equity of -62.26% is in line compared to the rest of the industry. SCYX outperforms 50.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -36.79% | ||
| ROE | -62.26% | ||
| ROIC | N/A |
ROA(3y)-15.59%
ROA(5y)-38.9%
ROE(3y)-650.17%
ROE(5y)-521.79%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for SCYX so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
SCYX does not have a ROIC to compare to the WACC, probably because it is not profitable.
SCYX has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, SCYX has more shares outstanding
The debt/assets ratio for SCYX has been reduced compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of -5.69, we must say that SCYX is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -5.69, SCYX is not doing good in the industry: 65.79% of the companies in the same industry are doing better.
SCYX has a Debt/Equity ratio of 0.23. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.23, SCYX is in line with its industry, outperforming 42.63% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.23 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -5.69 |
ROIC/WACCN/A
WACC11.24%
2.3 Liquidity
SCYX has a Current Ratio of 3.13. This indicates that SCYX is financially healthy and has no problem in meeting its short term obligations.
SCYX has a Current ratio of 3.13. This is comparable to the rest of the industry: SCYX outperforms 51.05% of its industry peers.
A Quick Ratio of 3.13 indicates that SCYX has no problem at all paying its short term obligations.
The Quick ratio of SCYX (3.13) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.13 | ||
| Quick Ratio | 3.13 |
3. Growth
3.1 Past
The earnings per share for SCYX have decreased strongly by -155.22% in the last year.
SCYX shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -93.70%.
Measured over the past years, SCYX shows a very strong growth in Revenue. The Revenue has been growing by 251.82% on average per year.
EPS 1Y (TTM)-155.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-50%
Revenue 1Y (TTM)-93.7%
Revenue growth 3YN/A
Revenue growth 5Y251.82%
Sales Q2Q%-62.52%
3.2 Future
Based on estimates for the next years, SCYX will show a very negative growth in Earnings Per Share. The EPS will decrease by -19.96% on average per year.
The Revenue is expected to decrease by -12.44% on average over the next years. This is quite bad
EPS Next Y-143.27%
EPS Next 2Y-46.61%
EPS Next 3Y-18.26%
EPS Next 5Y-19.96%
Revenue Next Year-92.3%
Revenue Next 2Y-37.61%
Revenue Next 3Y-6.49%
Revenue Next 5Y-12.44%
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for SCYX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SCYX. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
SCYX's earnings are expected to decrease with -18.26% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-46.61%
EPS Next 3Y-18.26%
5. Dividend
5.1 Amount
No dividends for SCYX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
SCYNEXIS INC
NASDAQ:SCYX (12/20/2024, 8:00:01 PM)
0.9999
-0.01 (-1%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners44.65%
Inst Owner Change-9.34%
Ins Owners1.23%
Ins Owner Change0.51%
Market Cap37.95M
Analysts85.45
Price Target7.01 (601.07%)
Short Float %2.12%
Short Ratio4.69
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-12.55%
Min EPS beat(2)-45.6%
Max EPS beat(2)20.51%
EPS beat(4)2
Avg EPS beat(4)-2.83%
Min EPS beat(4)-91.18%
Max EPS beat(4)104.96%
EPS beat(8)5
Avg EPS beat(8)-1.9%
EPS beat(12)7
Avg EPS beat(12)4.62%
EPS beat(16)10
Avg EPS beat(16)0.64%
Revenue beat(2)1
Avg Revenue beat(2)37.78%
Min Revenue beat(2)-89.53%
Max Revenue beat(2)165.09%
Revenue beat(4)3
Avg Revenue beat(4)183.69%
Min Revenue beat(4)-89.53%
Max Revenue beat(4)344.25%
Revenue beat(8)6
Avg Revenue beat(8)90.61%
Revenue beat(12)6
Avg Revenue beat(12)49.19%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-899.89%
EPS NY rev (1m)-22.4%
EPS NY rev (3m)-30.23%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-44.33%
Revenue NY rev (1m)-41.58%
Revenue NY rev (3m)-46.37%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 4.43 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.65 | ||
| P/tB | 0.65 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.74
EYN/A
EPS(NY)-0.2
Fwd EYN/A
FCF(TTM)-0.58
FCFYN/A
OCF(TTM)-0.58
OCFYN/A
SpS0.23
BVpS1.54
TBVpS1.54
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -36.79% | ||
| ROE | -62.26% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-15.59%
ROA(5y)-38.9%
ROE(3y)-650.17%
ROE(5y)-521.79%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.09
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.23 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.13 | ||
| Quick Ratio | 3.13 | ||
| Altman-Z | -5.69 |
F-Score2
WACC11.24%
ROIC/WACCN/A
Cap/Depr(3y)103.18%
Cap/Depr(5y)61.91%
Cap/Sales(3y)3.03%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-155.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-50%
EPS Next Y-143.27%
EPS Next 2Y-46.61%
EPS Next 3Y-18.26%
EPS Next 5Y-19.96%
Revenue 1Y (TTM)-93.7%
Revenue growth 3YN/A
Revenue growth 5Y251.82%
Sales Q2Q%-62.52%
Revenue Next Year-92.3%
Revenue Next 2Y-37.61%
Revenue Next 3Y-6.49%
Revenue Next 5Y-12.44%
EBIT growth 1Y-171.22%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y73.76%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y73.57%
OCF growth 3YN/A
OCF growth 5YN/A